Abstract
BACKGROUND: Serum levels of S-100B protein (S-100B) and neuron-specific enolase (NSE) are elevated after various cerebral injuries and are considered markers of central nervous system damage. In brain tumor patients, literature data on the prognostic value of serum S-100(B) and NSE levels are scarse and conflicting. PATIENTS AND METHODS: We assessed serum S-100B and NSE levels in 20 consecutive cerebral glioma patients, and evaluated serum levels in relation to survival to determine their prognostic value. Kaplan-Meier survival curves were constructed for patients with "high" (> median value) versus "low" ( <or = median value) serum S-100B and NSE levels. RESULTS: A statistically significant shorter survival was found in patients with high serum S-100B levels, whereas a similar classification of patients based on serum NSE levels demonstrated no statistically significant difference in survival between the two groups. CONCLUSION: These preliminary data suggest that serum S-100B might be a prognostic variable in cerebral glioma patients. Further study is warranted to evaluate whether serum S-100B is an additional, independent prognostic variable
| Original language | English |
|---|---|
| Pages (from-to) | 2511-2514 |
| Number of pages | 4 |
| Journal | Anticancer research |
| Volume | 24 |
| Issue number | 4 |
| Publication status | Published - 28 Aug 2004 |
Keywords
- Adult
- Brain Neoplasms/blood
- Female
- Glioma/blood
- Humans
- Male
- Middle Aged
- Nerve Growth Factors
- Phosphopyruvate Hydratase/blood
- Pilot Projects
- Prognosis
- S100 Calcium Binding Protein beta Subunit
- S100 Proteins/blood